About Us
Founder Story
In September 2024, I was diagnosed with stage IV rectal cancer in Toronto. My treatment has included FOLFOXIRI plus bevacizumab (January 2025), pelvic chemoradiation (April 2025), a combined low anterior resection (LAR) and liver resection (June 2025), a right hepatectomy (December 2025), and a VATS lung wedge resection on a single lung nodule (February 2026).
At this time, there is no evidence of disease, and my most recent Signatera test was negative.
As I started researching the clinical trial landscape, I realized something was missing.
Using every trial-finder and cancer app available, I kept running into the same problem: tools that weren't built for how patients actually decide. They lacked innovation, didn't explain what the drugs actually do, offered no real data on results or interim outcomes, and left me without a full understanding of whether a trial was truly worth considering.
As both a patient and a builder, I set out to change that—creating purpose-built CRC tools for patients and coordinators, not just another database. That became Second Look Cancer.
